Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-548

Now that 60% have been enrolled, I believe that there is a very good chance that the latest ones that got the shot must have been out of hospital by now. This would have left more and more doctors amazed. Novartis would have had some idea about it and wouldn't have done the deal without any knowledge. I have a feeling that 60% results will be good enough to get the approval.

Even if it's not, with Novartis involved things will be much faster now from further enrolment to data checking. We were on the back burner so far but now Novartis involvement will give us top priority. For Novartis, what they need to pay MSB is decided but how much money they end up making from Covid ARDS depends on the speed of trials and approvals. They would like to see sales happening in various countries asap to make most of this agreement. I believe that MSB will start benefitting form this deal very soon and very big.